Your browser doesn't support javascript.
loading
Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.
Gerson, James N; Handorf, Elizabeth; Villa, Diego; Gerrie, Alina S; Chapani, Parv; Li, Shaoying; Medeiros, L Jeffrey; Wang, Michael I; Cohen, Jonathon B; Calzada, Oscar; Churnetski, Michael C; Hill, Brian T; Sawalha, Yazeed; Hernandez-Ilizaliturri, Francisco J; Kothari, Shalin; Vose, Julie M; Bast, Martin A; Fenske, Timothy S; Narayana Rao Gari, Swapna; Maddocks, Kami J; Bond, David; Bachanova, Veronika; Kolla, Bhaskar; Chavez, Julio; Shah, Bijal; Lansigan, Frederick; Burns, Timothy F; Donovan, Alexandra M; Wagner-Johnston, Nina; Messmer, Marcus; Mehta, Amitkumar; Anderson, Jennifer K; Reddy, Nishitha; Kovach, Alexandra E; Landsburg, Daniel J; Glenn, Martha; Inwards, David J; Karmali, Reem; Kaplan, Jason B; Caimi, Paolo F; Rajguru, Saurabh; Evens, Andrew; Klein, Andreas; Umyarova, Elvira; Pulluri, Bhargavi; Amengual, Jennifer E; Lue, Jennifer K; Diefenbach, Catherine; Fisher, Richard I; Barta, Stefan K.
Afiliação
  • Gerson JN; 1 Fox Chase Cancer Center, Philadelphia, PA.
  • Handorf E; 1 Fox Chase Cancer Center, Philadelphia, PA.
  • Villa D; 2 BC Cancer, Vancouver, British Columbia, Canada.
  • Gerrie AS; 2 BC Cancer, Vancouver, British Columbia, Canada.
  • Chapani P; 2 BC Cancer, Vancouver, British Columbia, Canada.
  • Li S; 3 MD Anderson Cancer Center, Houston, TX.
  • Medeiros LJ; 3 MD Anderson Cancer Center, Houston, TX.
  • Wang MI; 3 MD Anderson Cancer Center, Houston, TX.
  • Cohen JB; 4 Emory University, Atlanta, GA.
  • Calzada O; 4 Emory University, Atlanta, GA.
  • Churnetski MC; 4 Emory University, Atlanta, GA.
  • Hill BT; 5 Cleveland Clinic Foundation, Cleveland, OH.
  • Sawalha Y; 5 Cleveland Clinic Foundation, Cleveland, OH.
  • Hernandez-Ilizaliturri FJ; 6 Roswell Park Cancer Institute, Buffalo, NY.
  • Kothari S; 6 Roswell Park Cancer Institute, Buffalo, NY.
  • Vose JM; 7 University of Nebraska Cancer Center, Omaha, NE.
  • Bast MA; 7 University of Nebraska Cancer Center, Omaha, NE.
  • Fenske TS; 8 Medical College of Wisconsin, Milwaukee, WI.
  • Narayana Rao Gari S; 8 Medical College of Wisconsin, Milwaukee, WI.
  • Maddocks KJ; 9 Ohio State University; Columbus, OH.
  • Bond D; 9 Ohio State University; Columbus, OH.
  • Bachanova V; 10 University of Minnesota, Minneapolis, MN.
  • Kolla B; 10 University of Minnesota, Minneapolis, MN.
  • Chavez J; 11 Moffitt Cancer Center, Tampa, FL.
  • Shah B; 11 Moffitt Cancer Center, Tampa, FL.
  • Lansigan F; 12 Dartmouth-Hitchcock Medical Center, Lebanon, NH.
  • Burns TF; 12 Dartmouth-Hitchcock Medical Center, Lebanon, NH.
  • Donovan AM; 12 Dartmouth-Hitchcock Medical Center, Lebanon, NH.
  • Wagner-Johnston N; 13 Johns Hopkins University, Baltimore, MD.
  • Messmer M; 13 Johns Hopkins University, Baltimore, MD.
  • Mehta A; 14 University of Alabama Cancer Center, Birmingham, AL.
  • Anderson JK; 14 University of Alabama Cancer Center, Birmingham, AL.
  • Reddy N; 15 Vanderbilt Ingram Cancer Center, Nashville, TN.
  • Kovach AE; 15 Vanderbilt Ingram Cancer Center, Nashville, TN.
  • Landsburg DJ; 16 University of Pennsylvania, Philadelphia, PA.
  • Glenn M; 17 Huntsman Cancer Institute, Salt Lake City, UT.
  • Inwards DJ; 18 Mayo Clinic, Rochester, MN.
  • Karmali R; 19 Northwestern University, Evanston, IL.
  • Kaplan JB; 19 Northwestern University, Evanston, IL.
  • Caimi PF; 20 Case Western Reserve University, Cleveland, OH.
  • Rajguru S; 21 University of Wisconsin, Madison, WI.
  • Evens A; 22 Tufts University, Boston, MA.
  • Klein A; 22 Tufts University, Boston, MA.
  • Umyarova E; 23 University of Vermont, Burlington, VT.
  • Pulluri B; 23 University of Vermont, Burlington, VT.
  • Amengual JE; 24 Columbia University, New York, NY.
  • Lue JK; 24 Columbia University, New York, NY.
  • Diefenbach C; 25 New York University, New York, NY.
  • Fisher RI; 1 Fox Chase Cancer Center, Philadelphia, PA.
  • Barta SK; 1 Fox Chase Cancer Center, Philadelphia, PA.
J Clin Oncol ; 37(6): 471-480, 2019 02 20.
Article em En | MEDLINE | ID: mdl-30615550
ABSTRACT

PURPOSE:

Mantle cell lymphoma (MCL) is a B-cell lymphoma characterized by cyclin D1 expression. Autologous hematopoietic cell transplantation (AHCT) consolidation after induction chemotherapy is often used for eligible patients; however, the benefit remains uncertain in the rituximab era. Herein we retrospectively assessed the impact of AHCT consolidation on survival in a large cohort of transplantation-eligible patients age 65 years or younger. PATIENTS AND

METHODS:

We retrospectively studied transplantation-eligible adults age 65 years or younger with newly diagnosed MCL treated between 2000 and 2015. The primary objective was to assess for improved progression-free survival (PFS) with AHCT consolidation and secondarily to assess for improved overall survival (OS). Cox multivariable regression analysis and propensity score-weighted (PSW) analysis were performed.

RESULTS:

Data were collected from 25 medical centers for 1,254 patients; 1,029 met inclusion criteria. Median follow-up for the cohort was 76 months. Median PFS and OS were 62 and 139 months, respectively. On unadjusted analysis, AHCT was associated with improved PFS (75 v 44 months with v without AHCT, respectively; P < .01) and OS (147 v 115 months with v without AHCT, respectively; P < .05). On multivariable regression analysis, AHCT was associated with improved PFS (hazard ratio [HR], 0.54; 95% CI, 0.44 to 0.66; P < .01) and a trend toward improved OS (HR, 0.77; 95% CI, 0.59 to 1.01; P = .06). After PSW analysis, AHCT remained associated with improved PFS (HR, 0.70; 95% CI, 0.59 to 0.84; P < .05) but not improved OS (HR, 0.87; 95% CI, 0.69 to 1.1; P = .2).

CONCLUSION:

In this large cohort of younger, transplantation-eligible patients with MCL, AHCT consolidation after induction was associated with significantly improved PFS but not OS after PSW analysis. Within the limitations of a retrospective analysis, our findings suggest that in younger, fit patients, AHCT consolidation may improve PFS.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Transplante de Células-Tronco Hematopoéticas / Linfoma de Célula do Manto / Rituximab / Antineoplásicos Imunológicos Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País como assunto: America do norte Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Transplante de Células-Tronco Hematopoéticas / Linfoma de Célula do Manto / Rituximab / Antineoplásicos Imunológicos Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País como assunto: America do norte Idioma: En Ano de publicação: 2019 Tipo de documento: Article